Skip to main content
Equibles
LBRX logo

LBRX · Lb Pharmaceuticals Inc

Track LBRX — free

Use LBRX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research LBRX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$44.63 -1.62 (-3.50%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$1.44B
Shares
32.26M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$44.63 Open$46.80 Day$44.40–47.68 52W close$14.61–49.48 Avg vol 30d321K Short int5.3M · 16.4% float · 19.9d Short vol72% DataSep 2025–Sep 2026 Filing10-Q · Aug 11

Up next

Latest filing: 10-Q
filed Aug 11, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$85.69M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
2.0
Trailing earnings · reciprocal yield 51.2%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$327.79M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+8,299.3%
Year over year · more shares
Price change (1Y)
+158.0%
Trailing year
Short interest
16.4%
Latest settlement · 19.9 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.58
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +52%
above
Price vs 50-day avg +7%
above
RSI (14) 46
neutral
MACD trend Negative
52-week position 86%
near high
Momentum
relative strength
Very Strong
1-month return +1%
trailing
6-month return +90%
trailing
YTD return +100%
this year
Relative strength +72%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $42 › 200d $29 — 50d above 200d
Institutional flow Accumulating
+48% holders QoQ · +42 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
16.36% of float · ▲ +2.4% MoM · 19.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
114 holders — near 1-yr high, broad support
Squeeze score 82
high risk · 0–100
Fundamentals
Fair
EPS growth +98%
Y/Y
Free cash flow $-35.3M
Quant / Vol
risk profile
Very High
Volatility 63%
annualized · 1-yr
Max drawdown −18%
past year
ATR 5.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
1 · 2 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+52% Bullish
Price vs 50-day avg
+7% Bullish
RSI (14)
46 Neutral
MACD trend
Negative Bearish
52-week position
86% Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $42 › 200d $29 — 50d above 200d
Institutional flow Accumulating
+48% holders QoQ · +42 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
16.36% of float · ▲ +2.4% MoM · 19.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
114 holders — near 1-yr high, broad support
Price context
position in its 52-week range
Range low $15 Now $45 · 86% Range high $49
vs 200-day avg +52% vs 50-day avg +7%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
LBRX
Lb Pharmaceuticals Inc
this stock
$1.44B +100.5% — — 16.4%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.64B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.22B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
114
% held
92.2%
Net QoQ
+1.5M sh
Top holder
Deep Track Capital, LP
Held Float
View
Held by Funds
Fund positions
125
View
Short & Settlement
Short Interest Rising
Shares short
5.3M
Days to cover
19.9d
Change
+122.1K sh
View
Short Volume
Short vol %
72%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
261
Value
$12.0K
As of
Aug 11, 2026
View
Off-Exchange
Off-exchange %
52.6%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-25.2M
EPS diluted
$-3.13
View
Filings
SEC Filings
Latest
8-K
Filed
Sep 3, 2026
This year
17
View
Proposed Sales
Value
$486.6K
Shares
16.5K
Filed
Jun 9, 2026
View
Exempt Offerings
Offering
$110.7M
Filed
Jan 10, 2024
View
Earnings & Events
Earnings Calls Upcoming
Next call
Sep 14, 2026
Last call
Jun 16, 2026
View
Investor Relations
Upcoming events
2
View

Performance

5D 20D 120D MTD YTD
LBRX -6.1% +0.8% +89.7% -5.6% +100.5%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -4.9% +2.6% +71.8% -5.2% +88.4%
Key facts CIK 1691082 CUSIP 50180M108 13F (30d) 51 filings 51 filers Visit website Investor relations